FindTrial
Sign In

Exploring the value of PGRMC1-mediated bilirubin metabolism gene polymorphism as a potential predictor of antipsychotic-induced lipid metabolism disorders

Exploring the value of PGRMC1-mediated bilirubin metabolism gene polymorphism as a potential predictor of antipsychotic-induced lipid metabolism disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048968
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disturbance of lipid metabolism

Interventions

Schizophrenia group:None
Bipolar disorder group:None

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients were diagnosed schizophrenia and bipolar disorder according to DSM-5/CCMD-3; 2. Aged 18-65 years; 3. Patients accepted antipsychotic drugs treatment at least two weeks.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Patients with severe liver diseases such as viral hepatitis, liver cirrhosis, drug-induced liver damage, and liver cancer upon admission; 3. Patients without laboratory test results; 4. Smoking and drinking.

Design outcomes

Primary

MeasureTime frame
Genetic mutations;Liver function parameters;Lipid metabolism parameters;—

Secondary

MeasureTime frame
Renal function parameters;Plasma concentration;Blood routine examination;—

Countries

China

Contacts

Public ContactCai Hualin

The Second Xiangya Hospital, Central South University

hualincai@csu.edu.cn+86 13755087574

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026